The content on this site is intended for healthcare professionals only
Dr Caio Rocha Lima speaks to ecancer about the phase III COMMIT trial, combining atezolizumab with FOLFOXIRI plus bevacizumab significantly improved outcomes compared with atezolizumab alone in treatment-naïve dMMR/MSI-H metastatic colorectal cancer.
Dr Rocha Lima highlights that at interim analysis, FFX/bev + atezolizumab reduced the risk of progression by 56% (HR 0.44; P=0.0103), with a median PFS of 30.0 months versus 4.3 months for atezolizumab monotherapy.
Objective response and disease control rates were also substantially higher with the combination, though with increased grade ≥3 adverse events.
Dr Rocha Lima concludes by saying that these results support dual immunotherapy and VEGF inhibition with chemotherapy as a more effective frontline strategy in dMMR/MSI-H mCRC.
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer
Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform
Toripalimab plus chemotherapy improves 3-year survival in resectable gastric/GEJ cancer
Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors
Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer
Zanzalintinib plus atezolizumab improves survival in refractory mCRC
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
